Immunotherapy — Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
Citation(s)
A Single-arm Multicenter Phase II Clinical Trial of Cadunilumab (Anti-PD-1/CTLA-4) in Combination With or Without Chemotherapy in Second-line Treatment for Patients With Extensive Stage Small Cell Lung Cancer